A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Blacksmith Medicines and Zoetis Announce Research Collaboration for Novel Animal Health Antibiotics

What To Know

  • (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, and Zoetis, the world’s leading animal health company, announced today a collaboration to discover and develop novel antibiotics for animal health.
  • “As part of our commitment to reduce the dependency on antibiotic classes shared with human health, we are pleased to leverage our veterinary expertise along with our extensive collection of pathogens in this collaboration with Blacksmith.

Novel Antibiotics for Animal Health

Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, and Zoetis, the world’s leading animal health company, announced today a collaboration to discover and develop novel antibiotics for animal health.

Zachary Zimmerman, Ph.D., CEO and co-founder of Blacksmith

“According to authorities including the FDA, CDC, WHO, WOAH, and EMA, antibiotic resistance can spread between animals & humans and this is particularly devastating for antibiotics that are the last line of treatment for critical infections in people.  Blacksmith and Zoetis will collaborate to discover and develop novel antibiotics to selectively target bacteria for animal health. This new collaboration is another example of Blacksmith’s creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.”

Dr. Jeff Watts, Research Director, External Innovation at Zoetis

“As part of our commitment to reduce the dependency on antibiotic classes shared with human health, we are pleased to leverage our veterinary expertise along with our extensive collection of pathogens in this collaboration with Blacksmith. Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock.”

About metalloenzymes and the Blacksmith platform

Metalloenzymes utilize a metal ion cofactor in the enzyme active site to perform essential biological functions.  This diverse class of targets has historically been difficult to drug due to small molecule chemistry limitations that have plagued the industry.  The Blacksmith metalloenzyme platform has solved this problem by leveraging the following:

  • A large proprietary fragment library of metal-binding pharmacophores (MBPs);
  • A comprehensive database containing a full characterization of the metalloenzyme genome including functions, metal cofactors, and associations to disease;
  • A first-of-its-kind metallo-CRISPR library of custom single guide RNAs;
  • An industry-leading metalloenzyme computational toolkit for docking, modeling and structure-based drug design; and
  • A robust and blocking intellectual property estate covering bioinorganic, medicinal, and computational chemistry approaches for metalloenzyme-targeted medicines.
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.
The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.
"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."
The relationship between pharmaceutical companies and CDMOs is fundamentally collaborative, fostering an environment of innovation. By partnering with a CDMO, pharmaceutical firms can access a wide array of technologies and expertise that might otherwise be beyond their reach.
Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.

By using this website you agree to accept Medical Device News Magazine Privacy Policy